Cargando…

Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer

Immune regulation has been shown to be involved in the progressive growth of some murine tumours. Interruption of immune regulatory pathways via activation of 4-1BB or cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blockade appears to be a promising strategy for cancer immunotherapy. In this s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Youlin, Kuang, Li, Zhang, Xiaodong, Weng, Xiuheng, Liu, Hengchen, Zhu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3270651/ https://www.ncbi.nlm.nih.gov/pubmed/22312406 http://dx.doi.org/10.1155/2012/439235

Ejemplares similares

The Change of Immunoactivity of Dendritic Cells Induced by Mouse 4-1BBL Recombinant Adenovirus
por: Youlin, Kuang, et al.
Publicado: (2010)

4-1BBL has a Possible Role in Mediating Castration-Resistant Conversion of Prostate Cancer via Up-Regulation of Androgen Receptor
por: Zhu, Hengcheng, et al.
Publicado: (2019)

Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
por: Wada, Satoshi, et al.
Publicado: (2013)

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
por: Du, Xuexiang, et al.
Publicado: (2018)

Multimeric forms of 4-1BBL as stimulators of T cells for adoptive immunotherapy
por: Kornbluth, Richard S, et al.
Publicado: (2014)

CTLA-4 blockade: therapeutic potential in cancer treatments
por: Tarhini, Ahmad A, et al.
Publicado: (2010)

Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival
por: Broucek, Joseph R, et al.
Publicado: (2013)

S43. Dendritic cell vaccination combined with CTLA4 blockade
por: Thielemans, K, et al.
Publicado: (2014)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
por: Fan, Xiaozhou, et al.
Publicado: (2014)

Blockade of 4-1BB and 4-1BBL Interaction Reduces Obesity-Induced Skeletal Muscle Inflammation
por: Le, Ngoc Hoan, et al.
Publicado: (2013)

Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity
por: Alvarez, Maite, et al.
Publicado: (2019)

Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
por: Tang, Fei, et al.
Publicado: (2018)

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
por: Sobhani, Navid, et al.
Publicado: (2021)

Radiotherapy enhances responses of lung cancer to CTLA-4 blockade
por: Wilkins, Anna, et al.
Publicado: (2019)

Radiotherapy induces responses of lung cancer to CTLA-4 blockade
por: Formenti, Silvia C., et al.
Publicado: (2018)

Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity
por: Watanabe, Tomofumi, et al.
Publicado: (2023)

Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma
por: Retseck, Janet, et al.
Publicado: (2018)

Antimesothelioma Immunotherapy by CTLA-4 Blockade Depends on Active PD1-Based TWIST1 Vaccination
por: Tan, Zhiwu, et al.
Publicado: (2020)

CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade
por: Vackova, Julie, et al.
Publicado: (2021)

Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models
por: Maruoka, Yasuhiro, et al.
Publicado: (2020)

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
por: Peggs, Karl S., et al.
Publicado: (2009)

CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
por: Waitz, Rebecca, et al.
Publicado: (2012)

Protective Immunity to Nematode Infection Is Induced by CTLA-4 Blockade
por: McCoy, Kathy, et al.
Publicado: (1997)

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
por: Kreidieh, Firas Y., et al.
Publicado: (2023)

Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection
por: vom Berg, Johannes, et al.
Publicado: (2013)

Recombinant salmonella-based 4-1BBL vaccine enhances T cell immunity and inhibits the development of colorectal cancer in rats: in vivo effects of vaccine containing 4-1BBL
por: Ye, Jianxin, et al.
Publicado: (2013)

CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
por: Camacho, Luis H
Publicado: (2015)

The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology
por: Zhang, Shashuang, et al.
Publicado: (2020)

A T cell repertoire timestamp is at the core of responsiveness to CTLA-4 blockade
por: Philip, Hagit, et al.
Publicado: (2021)

CTLA-4 checkpoint blockade in breast cancer, a case in point report
por: Dellepiane, Chiara, et al.
Publicado: (2015)

Current perspectives of SA-4-1BBL in immune modulation during cancer
por: Zhou, Shu-Ni, et al.
Publicado: (2018)

Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma
por: Lussier, Danielle M, et al.
Publicado: (2015)

Combination of CTLA-4 and PD-1 blockers for treatment of cancer
por: Rotte, Anand
Publicado: (2019)

Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts
por: Linch, Stefanie N, et al.
Publicado: (2014)

ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity
por: Soldevilla, Mario Martínez, et al.
Publicado: (2019)

Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial
por: Ott, Patrick A, et al.
Publicado: (2021)

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
por: von Euw, Erika, et al.
Publicado: (2009)

Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models
por: Jure-Kunkel, Maria, et al.
Publicado: (2013)

CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumors
por: Zappasodi, Roberta, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uh92haqjgbiq8osikn0ng469d6